Tarlatamab
| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Human |
| Target | DLL3 and CD3 |
| Clinical data | |
| Trade names | Imdelltra |
| Other names | AMG757; AMG-757, tarlatamab-dlle |
| AHFS/Drugs.com | Multum Consumer Information |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C4664H7139N1259O1454S34 |
| Molar mass | 105202.82 g·mol−1 |
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer.[5] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.[5]
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.[6]
Tarlatamab was approved for medical use in the United States in May 2024.[6][7] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[8]
- ^ "Summary Basis of Decision for Imdelltra". Drug and Health Products Portal. 11 February 2025. Retrieved 22 June 2025.
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-12-20]". Health Canada. 20 December 2024. Retrieved 21 December 2024.
- ^ "Imdelltra product information". Health Canada. 11 October 2024. Retrieved 27 December 2024.
- ^ "Regulatory Decision Summary for Imdelltra". Drug and Health Products Portal. 11 September 2024. Retrieved 27 December 2024.
- ^ a b c "Imdelltra (AMG757)- tarlatamab-dlle kit". DailyMed. 16 May 2024. Retrieved 31 May 2024.
- ^ a b "FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer". U.S. Food and Drug Administration (FDA). 16 May 2024. Retrieved 17 May 2024. This article incorporates text from this source, which is in the public domain.
- ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 19 April 2024. Retrieved 29 November 2024.
- ^ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.